Despite progress in recent years in the prevention, detection, and treatment of high blood pressure (BP), hypertension remains an important public health challenge. Hypertension affects approximately 1 billion individuals worldwide. High BP is associated with an increased risk of mortality and morbidity from stroke, coronary heart disease, congestive heart failure, and end-stage renal disease; it also has a negative impact on the quality of life. Hypertension cannot be eliminated because there are no vaccines to prevent the development of hypertension, but, its incidence can be decreased by reducing the risk factors for its development, which include obesity, high dietary intake of fat and sodium and low intake of potassium, physical inactivity, smoking, and excessive alcohol intake. For established hypertension, efforts are to be directed to control BP by lifestyle modification (LSM). However, if BP cannot be adequately controlled with LSM, then pharmacotherapy can be instituted along with LSM. Normalization of BP reduces cardiovascular risk (for cardiovascular death, myocardial infarction, and cardiac arrest), provides renoprotection (prevention of the onset or slowing of proteinuria and progression of renal dysfunction to end-stage renal disease in patients with hypertension, diabetes mellitus types 1 and 2, and chronic renal disease), and decreases the risk of cerebrovascular events (stroke and cognition impairment), as has been amply demonstrated by a large number of randomized clinical trials. In spite of the availability of more than 75 antihypertensive agents in 9 classes, BP control in the general population is at best inadequate. Therefore, antihypertensive therapy in the future or near future should be directed toward improving BP control in treated hypertensive patients with the available drugs by using the right combinations at optimum doses, individually tailored genepolymorphism directed therapy, or development of new modalities such as gene therapy and vaccines. Several studies have shown that BP can be reduced by lifestyle/behavior modification. Although, the reductions appear to be trivial, even small reductions in systolic BP (for example, 3-5 mm Hg) produce dramatic reduction in adverse cardiac events and stroke. On the basis of the results of clinical and clinical/observational studies, it has been recommended that more emphasis be placed on lifestyle/behavior modification (obesity, high dietary intake of fat and sodium, physical inactivity, smoking, excessive alcohol intake, low dietary potassium intake) to control BP and also to improve the efficacy of pharmacologic treatment of high BP. New classes of antihypertensive drugs and new compounds in the established drug classes are likely to widen the armamentarium available to combat hypertension. These include the aldosterone receptor blockers, vasodilator beta-blockers, renin inhibitors, endothelin receptor antagonists, and dual endopeptidase inhibitors. The use of fixed-dose combination drug therapy is likely to increase. There is a conceptual possibility that gene therapy may yield long-lasting antihypertensive effects by influencing the genes associated with hypertension. But, the treatment of human essential hypertension requires sustained over-expression of genes. Some of the challenging tasks for successful gene therapy that need to be mastered include identification of target genes, ideal gene transfer vector, precise delivery of genes into the required site (target), efficient transfer of genes into the cells of the target, and prompt assessment of gene expression over time. Targeting the RAS by antisense gene therapy appears to be a viable strategy for the long-term control of hypertension. Several problems that are encountered in the delivery of gene therapy include 1) low efficiency for 2) a lack of selectivity; 3) problem in determining how to prolong and control transgene expression or antisense inhibition; and 4) difficulty in minimizing the adverse effects of viral or nonviral vectors. In spite of the hurdles that face gene therapy administration in humans, studies in animals indicate that gene therapy may be feasible in treating human hypertension, albeit not in the near future. DNA testing for genetic polymorphism and determining the genotype of a patient may predict response to a certain class of antihypertensive agent and thus optimize therapy in individual patients. In this regard, there are some studies that report the effectiveness of antihypertensive therapy based upon the genotype of selected patients. Treatment of human hypertension with vaccines is feasible but is not likely to be available in the near future.
INTRODUCTION
Despite progress in recent years in the prevention, detection, and treatment of high blood pressure (BP), hypertension remains an important public health challenge. Hypertension affects approximately 50 million persons in the United States and approximately 1 billion individuals worldwide. 1 High BP is associated with an increased risk of mortality and morbidity from stroke, coronary heart disease, congestive heart failure, and end-stage renal disease. [2] [3] [4] A diagnosis of hypertension also has a negative impact on patient-reported quality of life (QOL). 5 Hypertension cannot be eliminated because there are no vaccines to prevent the development of hypertension, but its incidence can be decreased by reducing the risks for its development, which include obesity, high dietary intake of fat and sodium and low intake of potassium, physical inactivity, smoking, and excessive alcohol intake. Primary prevention of the development of hypertension provides an avenue to interrupt and prevent the continuing costly cycle of managing this disease and its complications. 6, 7 For established hypertension, efforts are to be directed to control BP by lifestyle modification (LSM). However, if BP cannot be adequately controlled with LSM, then pharmacotherapy can be instituted along with LSM. Normalization of BP reduces cardiovascular risk (for cardiovascular death, myocardial infarction, and cardiac arrest), provides renoprotection (prevention of the onset or slowing of proteinuria and progression of renal dysfunction to end-stage renal disease in patients with hypertension, diabetes mellitus (type 1 and 2), and chronic renal disease), and decreases the risk of cerebrovascular events (stroke and cognition impairment). This has been amply demonstrated by a large number of randomized clinical trials, which show that antihypertensive therapy results in a significant reduction in the morbidity and mortality In spite of the availability of more than 75 antihypertensive agents in 9 classes, BP control in the general population is at best inadequate (see below). Therefore, antihypertensive therapy in the future or near future should be directed toward improving BP control in treated hypertensive patients with the available drugs by using the right combinations at optimum doses, individually tailored gene-polymorphism directed therapy, or development of new modalities such as gene therapy and vaccines. 8 
WHAT IS A NORMAL BLOOD PRESSURE?
The definition of ''normal blood pressure'' has been changing in recent years. The 7th Joint National Committee (JNC) recommended a new classification system for hypertension. 1 According to this report, individuals can be classified based on the mean of two or more properly measured seated BP readings on each of two or more office visits. The JNC VII added a new category designated as ''prehypertension'' for patients with systolic BP between 120 and 139 mm Hg or a diastolic BP between 80 and 89 mm Hg. This change in classification is based on the findings from the Framingham Heart Study that patients with high normal BP (JNC VI classification: systolic BP between 130 and 139 mm Hg or a diastolic BP between 85 and 89 mm Hg) were at increased risk for progression to hypertension. 9 The JNC VII recommends that individuals with prehypertension engage in a healthpromoting LSM to prevent the development of hypertension and associated cardiovascular disease. The optimal BP for the diabetics should be 130/80 mm Hg, 120/70 mm Hg for patients with nephropathy and renal failure 120/70 mm Hg, and 125/75 mm Hg for patients with diabetes and nephropathy; [10] [11] [12] in some cases, even lower BP (,115/,75 mm Hg) is considered optimal. 1, 13 It may be pointed out that some European countries still maintain that a reading of 160/95 mm Hg is ''normal,'' 14 and patients in China are treated only if the BP is greater than 160/95 mm Hg. 15 
BLOOD PRESSURE CONTROL IN THE POPULATION
Despite efforts to increase awareness and detection of hypertension and advances in the therapy of hypertension, BP control still remains poor to very poor in most countries of the world (Table 1) . Hypertension control even in treated hypertensive patients in most countries, including the Western world is also inadequate: United States 40% to 55%, Canada 47%, England 40%, Russia 33%, Greece 20% to 33%, Germany 30%, Argentina 29%, Brazil 29%, China 20% to 29%, Italy 28%, Sweden 21%, Spain 19%, Turkey 8%. [14] [15] [16] [17] [18] [19] [20] [21] Control of isolated systolic hypertension, mainly in the elderly, still remains a challenge, 22 and elderly hypertensives have the poorest rate of BP control in the United States. 21, 23 Multiple patient-, physician-, and system-related factors that have been implicated in the underlying cause of poor BP control include poor access to health care, unhealthy lifestyle, suboptimal patient-physician interaction, poor disease education, health disparities, noncompliance with diet or drug regimen, adverse effects of therapy, and the use of less than optimal treatment regimens. 29, 30 The availability of drugs may be a factor in some patients, but studies show that the cost of medication is not as important as the adverse effects associated with the drugs. 31 To minimize adverse effects, clinicians should prescribe medications (drug class or dosing) that improve BP with the fewest adverse effects. 32 For example, the diuretics are more often associated with sexual dysfunction in men than any other drug classes, but lowering the dose can minimize this effect. 32 Patient education is extremely important to improve compliance with therapy. In some countries, patients do not understand the risks and consequences of having high BP. For example, almost 60% of patients in countries such as Nigeria and Saudi Arabia believe that psychosocial stress is the main cause of hypertension, and only 20% of hypertensive patients who suffered a stroke associated it with high BP. 33, 34 In many countries, the belief that ''natural therapies'' can permanently cure hypertension 33, 35 contributes to poor BP control.
Another factor that has been associated with poor compliance is the QOL, which plays a central role in noncompliance. 36 As the QOL declines, so does medication compliance. 32 The QOL is a multifaceted variable that includes the patient's experience of symptoms, as well as emotional, physical, work, social, and cognitive satisfaction. The numbers of symptoms experienced and the distress the drugs cause are more strongly associated with low QOL ratings than any other variable. 36 Lowering of BP with any drug class generally improves the QOL. 37 Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARBs) are associated with the highest positive QOL, including improved cognition and a lack of adverse effect on sexual function. Calcium channel blockers have a positive impact on QOL except for the short-acting, first-generation dihydropyridines, but the slow-release preparations of these agents do not have American Journal of Therapeutics (2007) 14 (2) The Future of Antihypertensive Treatmenta negative impact on QOL. 32 Nonselective lipophylic b-blockers have high negative impact on the QOL, including depression, impaired memory, and erectile dysfunction. 32, 38 It may be pointed out that most patients' medication can be managed to have no or minimal negative impact on QOL. In any therapeutic regimen, the QOL should be addressed to improve compliance.
Concerted efforts have to be made to improve BP control in treated hypertensive patients. An ongoing trial, ''MyBP,'' sponsored by National Heart, Lung, and Blood Institute, focuses on improving hypertension control by the use of home BP monitoring, electronic medical records, organized systems of care using clinical pharmacists, and secured communication between the patient and the clinical team. 20 A strategy, ''tailored feedback to patients and clinicians,'' has recently been suggested to improve BP control. 39 
NONPHARMACOLOGIC TREATMENT OF HIGH BLOOD PRESSURE

Reduction in blood pressure by lifestyle modification
Several studies [40] [41] [42] [43] [44] [45] [46] have shown that BP can be reduced by lifestyle/behavior modification ( Table 2) . Although the reductions appear to be trivial, even small reductions in systolic BP (3-5 mm Hg) produce dramatic reduction in adverse cardiac events and stroke. 47, 48 On the basis of the results of clinical 49 and clinical/ observational studies such as the PREMIER trial 42, 44, 50 and the DASH trial 41 and a meta-analysis, 50 it has been recommended that more emphasis be placed on lifestyle/behavior modification (obesity, high dietary intake of fat and sodium, physical inactivity, smoking, excessive alcohol intake, low dietary potassium intake) to control BP and also to improve the efficacy of pharmacologic treatment of high BP. To achieve maximum benefits, plans for diet, exercise, and other needed changes should be initiated in the primary care setting, and discussed with the patient, and appropriate goals should be established, which should be realistic. The recommendations to the patients should be specific, individually tailored, and well supported with counseling efforts and provision of effective patient education materials.
Miscellaneous techniques: meditation and yoga
A number of alternative approaches to pharmacologic treatment, such as stress reduction or stress management, relaxation biofeedback, transcendental meditation, yoga, prayer, acupuncture, and psychotherapy have been suggested to control high BP. Some of these techniques do decrease BP in prehypertensive or stage 1 hypertensive patients 51 and decrease mortality in hypertensive patients. 52 Some authors have claimed that evidence for the efficacy of some of these nonpharmacologic strategies to prevent and control high BP is strong. 53 These authors direct the clinicians to the U.S. National Heart, Lung and Blood Institute Website at www.nhlbi.gov/health/prof/heart/index. htm for resource and guideline information for hypertension and the patients and the general public to another website, www.nhlbi.gov/health/public/ heart/index.htm, for educational fact sheets and general information on hypertension. Stress reduction may be used as an adjunct to pharmacologic treatment of hypertension. 52 Blood pressure control with ''Natural'' medicine A large proportion of the population in developing countries believes that natural therapies provided by traditional healers (homeopaths, native doctors, and faith healers) can permanently cure hypertension. 35 In many countries, some 60% to 70% of the hypertensive patients consult traditional healers at one time or another. 35 Others claim that ''natural'' medicine can improve BP control without adverse effects.
There are dietary supplements with some evidence of benefit in humans. 54 The Natural Medicines Comprehensive Database (www.naturaldatabase.com) rates the following preparations as possibly effective in lowering BP: 1) coenzyme Q10, corrects an endogenous provitamin deficiency and also acts as an antioxidant; 2) fish oil, the omega-3 fatty acids in fish oil cause vasodilation because of modulation of intracellular calcium ion; 3) garlic, causes smooth muscle American Journal of Therapeutics (2007) 14 (2) relaxation and vasodilation, but the effect is very controversial; 4) vitamin C, as an antioxidant, might enhance the synthesis or prevent the breakdown of nitric oxide (NO); 5) L-arginine, as a substrate, it enhances NO synthesis. The same database lists hawthorn leaf extract and vitamin E as having very little or no evidence of benefit in humans. Dietary supplementation with the anti-oxidant lycopene in tomato juice, 55 soybean protein, 49 omega-3-fatty acids, 56 linolenic acid, 57 and tropical food drinks coconut water and mauby 58 lower BP in humans. Although the dietary supplements listed above show some evidence of benefit in humans, they should not be used as effective and safe alternatives to conventional medications to treat hypertension.
SOME NEWER ANTIHYPERTENSIVE DRUGS
New classes of antihypertensive drugs and new compounds in the established drug classes are likely to widen the armamentarium available to combat hypertension. These include the aldosterone receptor blockers, vasodilator b-blockers, renin inhibitors, endothelin receptor antagonists, and dual endopeptidase inhibitors. Only the specific aldosterone receptor blockers and the vasodilator b-blockers appear to be promising in treating systemic hypertension in routine clinical practice.
Aldosterone receptor blockers
Aldosterone, independent of angiotensin II, has been implicated in the pathogenesis of progressive cardiovascular 59, 60 and renal disease. 61 Aldosterone antagonists, with or without ACE inhibitors/ARBs, have proved to be as effective as other antihypertensive drugs in the treatment of high BP [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] and useful in reducing a variety of cardiovascular 60, 65, 74 and renal 61, 73 endpoints. The aldosterone antagonists are well tolerated; [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] however, the danger of hyperkalemia with aldosterone antagonists has been pointed out, especially in the elderly, diabetics, and heart failure patients with chronic renal disease, and those also receiving ACE inhibitors/ARBs or potassium supplement. 69, [76] [77] [78] It is expected that specific aldosterone receptor blockers will be used more often, especially in combination with other antihypertensive drugs.
Novel beta-blockers with vasodilator activity
The third generation b-blockers, carvedilol, celiprolol, and nevibolol, are also vasodilators. Their use is expected to increase in the treatment of hypertensive patients, especially with diastolic or systolic dysfunction.
Nevibolol, a highly selective b-1 blocker with an NO-mediated vasodilator effect, looks promising in controlling hypertension [79] [80] [81] [82] because it acts by two mechanisms. 83 The vasodilator effect of nebivolol on the renal artery involves 1) activation of the endothelial b-2-adrenoceptor, 2) participation of Ca2+, 3) increase in NO (by preventing its oxidative degradation) and eNOS, and 4) activation of Ca2+-activated K+ channels. 84 The tolerability of nebivolol is similar to that of the nonvasodilating b-blockers. Both the BP lowering effect and the vasodilating action is seen after single and chronic administration of the usual antihypertensive oral dose of 5 mg once daily. It has a favorable hemodynamic action on both systolic and diastolic function, which often complicates hypertension, especially an increase in stroke volume, associated with reduction in vascular resistance, resulting in a maintained cardiac output, despite reduced heart rate. These properties differentiate nebivolol from the nonvasodilating b-blockers, such as atenolol, metoprolol, or bisoprolol. 82 Nebivolol has a favorable effect on the prothrombotic state (decrease in plasma levels of fibrinogen and homocysteine and serum levels of plasminogen activator inhibitor [PAI]-1), especially in hypertensive smokers. 85 In addition, nebivolol may be used in the treatment of hypertensive patients with airway dysfunction. 86 Carvedilol, a nonselective b-blocker, provides hemodynamic, anti-ischemic, antiproliferative, antiarrhytmic, and antioxidant benefits, which make the drug useful in the treatment of hypertension, coronary heart disease, and congestive heart failure. 87, 88 Carvedilol, because of its vasodilating effect, could be advantageous in treating hypertensive patients with insulin resistance or type 2 diabetes. 89 However, unlike nebivolol, it does not have a beneficial effect on the prothrombic state (fibrinogen, homocysteine, and PAI-1). 85 Celiprolol, a cardioselective b-blocker with a stimulant effect on b-2 receptors, is as effective an antihypertensive agent as other b-blockers. 89, 90 Celiprolol is useful in treating hypercholesterolemic hypertensive patients because it improves lipid profile (decrease in total cholesterol, low density lipoprotein cholesterol, and triglycerides, and increase in high density lipoprotein cholesterol. 91 Because of its vasodilating effect, it could also be advantageous for hypertensive patients with insulin resistance or type 2 diabetes 89 or in patients with chronic glomerulonephritis and arterial hypertension. 92 Celiprolol may be used in the treatment of hypertensive patients with airway dysfunction. 86 Celiprolol also significantly affects prothrombic parameters (plasma levels of fibrinogen and homocysteine and serum levels of PAI-1) but to a lesser degree than nebivolol. 85 Celiprolol is not suitable in treating patients with heart failure, but it may used in patients with hypertension and angina or altered cardiac function. 93 
Renin inhibitors
Renin inhibitors represent a new class of drugs that suppress renin-angiotensin system (RAS) by blocking the action of renin on angiotensinogen to produce angiotensin I. The first renin inhibitor, aliskiren, when administered along with an angiotensin II receptor type-1 blocker (ARB), eliminated the ARB-induced rise in plasma renin activity (PRA). Orally administered aliskiren has been shown to be a well-tolerated and effective antihypertensive agent, with or without an ACE inhibitor or ARB.
94-95
Endothelin receptor antagonists
The inhibitors of endothelin receptors (A or A/B), such as bosantan, darusentan, sitaxsentan, and tezosentan, represent a newer class of antihypertensive drugs; however, they have been found to be useful mostly in treating pulmonary arterial hypertension.
96-98
Dual vasopeptidase inhibitors
These drugs, such as omapatrilat, which inhibit both the ACE and neutral endopeptidase, decrease BP in hypertensive patients, but their role in clinical practice still remains uncertain.
99,100
GENE THERAPY OF HYPERTENSION
It has been argued that the conventional antihypertensive therapies offer no long-term cure and may lead to patient noncompliance because of adverse effects. It is also possible that pharmacologic approaches may have reached a plateau in their effectiveness, thus necessitating the need for newer innovative strategies to improve BP control and possibly to cure hypertension. There is a conceptual possibility that gene therapy offers a potential to yield long-lasting antihypertensive effects by influencing the genes associated with hypertension. But, the treatment of human essential hypertension requires sustained over-expression of genes. Some of the challenging tasks for successful gene therapy that need to be mastered include identification of target genes, ideal gene transfer vector, precise delivery of genes into the required site (target), efficient transfer of genes into the cells of the target, and prompt assessment of gene expression over time.
The following studies in experimental hypertension indicate that antisense gene therapy is a conceptually valid strategy for the control of hypertension at the genetic level and may be applicable to human hypertension: Targeting the RAS by antisense gene therapy appears to be a viable strategy for the long-term control of hypertension. [104] [105] [106] [107] [108] Several problems that are encountered in the delivery of gene therapy include 1) low efficiency for gene transfer into vascular cells; 2) a lack of selectivity; 3) problem in determining how to prolong and control transgene expression or antisense inhibition; and 4) difficulty in minimizing the adverse effects of viral or nonviral vectors. In spite of the hurdles that face gene therapy administration in humans, studies in animals indicate that gene therapy may be feasible in treating human hypertension, albeit not in the near future.
THERAPY BASED UPON GENE POLYMORPHISM
Multiple genes are involved in the etiology of human hypertension, and variations in these genes may be linked to the development of hypertension. It appears that essential hypertension is the sum result of the individual small effect of polymorphisms in as yet unknown number of genes that influence BP in response to particular environmental influences. 109 In this regard, a number of strategies have been adopted, such as genome-wide scan for hypertension in sibships to identify possible hypertension loci on chromosomes (HyperGEN, 110 the BRIGHT study, 111 and the GENI-HUSS Study 112 ). The National Millennium Project of Japan has already investigated 100,000 single nucleotide polymorphism markers in an attempt to identify genetic variations linked to the development of hypertension. 113 Polymorphism in the genes encoding for a number of substances has been found to be associated with hypertension; some of these include 1) human atrial natriuretic peptide; 114 2) subunit of the epithelial Na+ channel; 115 131 DNA testing for genetic polymorphism and determining the genotype of a patient may predict response to a certain class of antihypertensive agent and thus optimize therapy in individual patients. In this regard, there are some studies that report the effectiveness of antihypertensive therapy based upon the genotype of selected patients. For example, 1) amiloride was found to be effective as monotherapy in hypertensive patients with Thr594Met polymorphism in the epithelial sodium channel who have increased amiloride-sensitive sodium channel activity, 132 2) the therapeutic response to the ARB losartan was much greater in patients on the basis of AT 1 receptor A1166C polymorphism, 133 3) the M235T polymorphism in the angiotensinogen gene was found to be an independent predictor of the BP response to ACE inhibition, 134 4) polymorphism in the GNAS1 locus, encoding the G(s) protein alpha-subunit (FokI allele) was related to the BP response to b-blockers, 131 and 5) single nucleotide polymorphisms in the angiotensinogen gene were associated with the BP lowering response to atenolol. 135 However, correlations between gene polymorphism and high BP are not consistent and are often limited to a certain ethnicity 126, 127 and sex, 128 and influenced by environmental factors. Therefore, it is too early to make any recommendation of a specific drug (class) for optimal treatment according to a patient's genotype.
Immunotherapy of hypertension
There are some recent developments in the area of immunotherapy of hypertension. Vaccination with an antigen containing an analog of angiotensin (Ang) I blocked the suppressor effect of exogenous Ang I in rats. 136 Studies with carrier proteins (used in conjugating the antigen for the vaccine) demonstrated that conjugation with keyhole limpet hemocyanin was superior to tetanus toxoid in generating antibody response to Ang I in both rats and humans. 137 In a small study, hypertensive patients responsive to an ACE inhibitor or ARB were given 3 or 4 injections of PMD3117, a vaccine based upon Ang I antigen over a 6 week period; 8 the antibody titer rose from the second injection and peaked in 6 weeks, but it was not enough to influence BP. However, it blunted the fall in plasma renin after withdrawal of the ACE inhibitor or ARB and decreased aldosterone excretion significantly, indicating suppression of the RAS. The authors believe that much higher titers will be required to have an influence on BP. Treatment of human hypertension with vaccines is feasible but is not likely to be available in the near future.
Combination therapy of hypertension
Because hypertension is a multifactorial disease, simply interfering with one of its pathophysiologic mechanisms by monotherapy is usually insufficient to control it. Treatment with a single antihypertensive agent will generally control BP in less than half of the patients, and more than 60% of the patients require combination therapy with two or more drugs of different classes to achieve target BP, as has been observed in a number of large clinical trials (for example, ALLHAT [138] [139] [140] [141] [142] [143] [144] [145] Black and elderly hypertensive patients require 2 or more drugs to control their BP. 144 According to the JNC7, persons with BP more than 20/10 mm Hg above goal should be started on combination drug therapy, including patients with BP greater than 160/100 mm Hg and diabetics with BP above the goal (,130/80 mm Hg). 1, 140 In diabetic patients with nephropathy, tight BP control is needed to prevent deterioration of end organ damage, which is difficult to achieve and usually necessitates the use of 3 to 5 different classes of antihypertensive agents. 146 New clinical trials are needed to determine optimal drug combinations that will also confer target-organ protection in addition to and independent of their BP lowering effects. In this regard, a large trial, ACCOMPLISH, is in progress that is comparing the combinations ACE inhibitor (benazepril)/CCB (amlodipine) and ACE inhibitor (benazepril)/diuretic. 147, 148 The recommendations for combination therapy for some special situations are listed in Table 3 , whereas poor or troublesome combinations are listed in Table 4 . Administration of an ACE inhibitor along with an ARB has been found to be more effective than the individual drugs in treating hypertensive patients with diabetic nephropathy [149] [150] [151] or those with severe hypertension. 152 Fixed drug combinations are often useful in optimizing the therapy of hypertension. Such combinations (approved in the United States) are usually with a diuretic (mostly hydrochlorothiazide) and an ACE inhibitor (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, or quinapril), an ARB (candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, or valsartan) or a b-blocker (bisoprolol, propranolol, metprolol, or timolol). Other diuretics have been combined with some b-blockers (atenolol + chlorthalidone and nadolol + bendroflumethiazide). Several other combinations include clonidine + chlorthalidone, benazepril + amlodipine, trandolapril + verapamil, and prazosin + polythiazide. Diuretics with different mechanisms of action have also been combined in some preparations (hydrochlorothiazide with amiloride, spironolactone, or triamterene).
Recently, a fixed combination of an antihypertensive agent with a statin (amlodipine/atorvastatin) has proven to be better than the antihypertensive drug alone in treating hypertensive patients. 153 This could be because statins alone lower BP, especially in saltsensitive patients. 154 Such combinations also reduce the Framingham cardiovascular risk score in hypertensive patients with dyslipidemia. 155 
WHICH CLASS OF ANTIHYPERTENSIVE DRUG IS BETTER THAN THE OTHERS?
It has been shown that reducing intra-arterial pressure is more important than the means by which it is reduced, 156 be it by LSM alone or a combination of LSM and pharmacologic agents. Furthermore, several randomized, clinical trials have documented that most of the antihypertensive drug classes reduce major cardiovascular endpoints such as heart attack, stroke, and congestive heart attack to a similar extent (see lists of studies cited earlier). However, in 1 study, compliance was better with valsartan than with amlodipine, hydrochlorothiazide, or lisinopril, 157 although valsartan was found not to be superior to amlodipine (the VALUE trial) in a head-to-head trial. 158 Treatment with specific drug class or drug combination may confer target-organ protection in addition to and independent of their BP lowering effects. There is substantial clinical evidence that ACE inhibitors are more suitable in hypertensive patients with diabetes, renal insufficiency, or proteinuria. More studies are needed to prove that the ARBs are also in the same category.
BEYOND BLOOD PRESSURE LOWERING: PLEITROPIC EFFECTS OF ANTIHYPERTENSIVE DRUGS
Reductions in BP by any drug class results in lower risk of cardiovascular and cerebrovascular events and often lower renal pathology. In addition, many drugs, especially those which interfere with the RAS, such as the ACE inhibitors and the ARBs, have pleiotropic properties that go beyond BP reduction and produce beneficial cardiovascular and renal effects in patients. The ACE inhibitors and the ARBs suppress factors that promote atherosclerosis, such as oxidative stress, inflammation, endothelial dysfunction, and impaired fibrinolysis, 159 and thereby reduce acute coronary events associated with atherosclerosis in patients without a history of myocardial infarction or heart failure. 160 The ACE inhibitors also decrease other risk factors for atherosclerosis, such as PAI-1, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, and endothelin-1, and increase NO, whereas the ARBs reduce vascular cell adhesion molecule-1 and Creactive protein. 159, 160 Both the ACE inhibitors and the ARBs play a role in the prevention of new onset type 2 diabetes.
161,162
CONCLUSIONS
Hypertension remains a serious health problem worldwide. Hypertension control strategies at the community levels are either nonexistent or inadequate. The control of BP is poor to very poor in most nations. Even in treated patients, BP control is less than 2, 13, 163 Which specific drug regimens (drug classes, combinations, doses, and time of drug administration) are optimal? Should drug regimens be individualized on the basis of genetic differences in drug response, genetic polymorphism, or subclinical markers of disease? How to reverse or at least stop the progression of renal disease, especially in hypertensive patients with diabetes? Moreover, in countries with poor resources, which drugs or combinations will provide the best medical and economic outcomes? Some of these questions have been addressed by The National Heart, Lung, and Blood Institute Working Group on Future Directions in Hypertension Treatment Trials. 164 
